SCHEMBL2587386

SCHEMBL2587386

CC(C)NC(=O)c1cccc2[nH]ncc12

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 11/20 0.53
KIT P10721 2/20 0.51
PRMT5 O14744 1/20 0.48
TRPV1 Q8NER1 4/20 0.48
DHPS P49366 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24112335 0.83 METTL3 (0.55) METTL3KITDHPS
SCHEMBL31719176 0.80 METTL3 (0.50) METTL3KITDHPS
SCHEMBL543898 0.80 METTL3 (0.50) METTL3KITDHPS
SCHEMBL459667 0.80 METTL3 (0.52) METTL3KITPRMT5
SCHEMBL28267337 0.79 KDM4E (0.48) METTL3KITTRPV1
SCHEMBL305699 0.79 METTL3 (0.55) METTL3KITPRMT5
Hydrochloric Acid SCHEMBL30715238 0.79 METTL3 (0.52) METTL3KITDHPS
SCHEMBL17738640 0.77 METAP2 (0.43)
SCHEMBL1695143 0.77 ROCK2 (0.44)
SCHEMBL260364 0.76 NOS1 (0.52) METTL3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-05-26 US disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 EP disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL METTL3 4296/4885KIT 2270/4885PRMT5 1651/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL METTL3 3639/4885KIT 3737/4885PRMT5 1998/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV METTL3 4414/4885KIT 2046/4885PRMT5 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.